2025年12月7日，在北京举行的创新药高质量发展大会上获悉，卫材的莱博雷生片和海南先声的盐酸达利雷生片均未纳入新版国家医保药品目录及商保创新药目录。这两款治疗睡眠障碍的新药此前已通过相关形式审查，具备参评资格。尽管产品在临床应用上有一定前景，但最终未能进入目录。业内人士指出，这可能与药物经济学评估、价格谈判等因素有关。目前患者使用该类药品仍需自费承担较高费用。
Source Link2025年12月7日，在北京举行的创新药高质量发展大会上获悉，卫材的莱博雷生片和海南先声的盐酸达利雷生片均未纳入新版国家医保药品目录及商保创新药目录。这两款治疗睡眠障碍的新药此前已通过相关形式审查，具备参评资格。尽管产品在临床应用上有一定前景，但最终未能进入目录。业内人士指出，这可能与药物经济学评估、价格谈判等因素有关。目前患者使用该类药品仍需自费承担较高费用。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.